

Cytogenetic Analysis of Acute Myeloid Leukemia with t(8;21): Its Clinical Correlation with Loss of X Chromosome and Del (9q)

Thesis

Submitted for Partial Fulfillment of M.D. Degree
in Clinical and Chemical Pathology

By

Heba Mohamed Atif Ismail

*M.B., B.Ch., M.Sc.(Clinical and Chemical Pathology)
Ain Shams University*

Supervised by

Prof. /Afaf Abd El Aziz Abd El Ghafar

*Professor of Clinical and Chemical Pathology
Faculty of Medicine – Ain Shams University*

Prof. / Abeer Attia Saadeldin

*Professor of Clinical and Chemical Pathology
Faculty of Medicine – Ain Shams University*

Dr./ Yasmin Nabil El-Sakhawy

*Lecturer of Clinical and Chemical Pathology
Faculty of Medicine – Ain Shams University*

Dr./ Nesma Ahmed Safwat

*Lecturer of Clinical and Chemical Pathology
Faculty of Medicine – Ain Shams University*

**Faculty of Medicine
Ain Shams University**

2016

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

قالوا

لسبحانك لا علم لنا
إلا ما علمتنا إنك أنت
العليم العظيم

صدق الله العظيم

سورة البقرة الآية: ٢٢



Acknowledgment

*First and foremost, I feel always indebted to **ALLAH**, the Most Kind and Most Merciful.*

*I'd like to express my respectful thanks and profound gratitude to **Prof. / Afaq Abd El Aziz Abd El Ghafar**, Professor of Clinical and Chemical Pathology, Faculty of Medicine, Ain Shams University for her keen guidance, kind supervision, valuable advice and **constant help** which made the completion of this work possible.*

*I am also delighted to express my deepest gratitude and thanks to **Prof. / Abeer Attia Saadeldin**, Professor of Clinical and Chemical Pathology, Faculty of Medicine, Ain Shams University, for her kind care, valuable instructions and great assistance throughout this work.*

*I am deeply thankful to **Dr./ Yasmin Nabil El-Sakhawy**, Lecturer of Clinical and Chemical Pathology, Faculty of Medicine, Ain Shams University, for her great help, active participation and guidance.*

*I wish to introduce my deep respect and thanks to **Dr./ Nesma Ahmed Safwat**, Lecturer of Clinical and Chemical Pathology, Faculty of Medicine, Ain Shams University, for her instructive supervision and cooperation in this work.*

No words could express my thanks to my dad, my mum, my husband, my son and my brothers for their great care and support till this work was completed and throughout my whole life.

Heba Atif

List of Contents

Title	Page No.
List of Tables	1
List of Figures.....	2
List of Photos	4
List of Abbreviations	5
Introduction	1
Aim of the Work	3
Review of Literature	
Chapter (1): Translocation (8;21) Acute Myeloid Leukemia	4
1.1. Molecular pathogenesis	5
1.2. Genetic abnormalities in combination with t(8,21):.....	8
1.3. Incidence of t(8;21).....	9
1.4. Diagnosis of t(8;21).....	9
1.5. Methods of cytogenetic and molecular analysis of t(8,21)	12
1.6. Disease prognosis and minimal residual disease detection	17
1.7. Treatment of t(8;21) patients	18
Chapter (2): Loss of X Chromosome.....	19
2.1. Incidence	19
2.2. Pathogenesis	19
2.3. Clinical Picture.....	22
2.4. Prognosis.....	22
Chapter (3): Deletion of the Long Arm of Chromosome 9	23
3.1. Incidence	23
3.2. Pathogenesis	23
3.3. Clinical picture	26
3.4. Cytologic characteristics	26
3.5. Prognosis.....	26
Subjects and Methods.....	27
Results	44
Discussion.....	73
Summary and Conclusion.....	83
Recommendations	86
References	87
Arabic Summary	

List of Tables

Table No.	Title	Page No.
Table (1):	Demographic, clinical and laboratory data of all the studied patients	49
Table (2):	Cytogenetic aberrations detected in all the studied patients	50
Table (3):	Clinical and laboratory characteristics in relation to del (9q)	51
Table (4):	Clinical and laboratory characteristics in relation to loss of X chromosome	52
Table (5):	Comparison between patients with negative del (9q) or loss of X chromosome and those with positive del (9q) or loss of X chromosome regarding all the variables	53
Table (6):	Clinical and laboratory characteristics in relation to response to therapy.	54
Table (7):	Clinical and laboratory characteristics in relation to disease outcome	55
Table (8):	Statistical analysis of the disease free survival of the studied patients	56
Table (9):	Statistical analysis of the overall survival of the studied patients	57

List of Figures

Fig. No.	Title	Page No.
Figure (1):	Scheme of translocation t(8;21)(q22;q22) resulting in formation of fused gene AML1-ETO.....	6
Figure (2):	Leukomogenesis by core binding factor.....	7
Figure (3):	(A): Marrow blasts of t(8;21) acute myeloid leukemia. (B): Bone marrow aspirate from a t(8;21)(q22;q22) acute myeloid leukemia case showing blasts with moderate amount of cytoplasm and prominent Auer rods.....	11
Figure (4):	G-banding showing t(8;21).....	13
Figure (5):	FISH analysis for the AML1/ETO probe	15
Figure (6):	Bone marrow cytogenetics showing t(8;21)(q22;q22) with loss of X chromosome	20
Figure (7):	G-banded karyotype showing del(X)(p21)	21
Figure (8):	Transcript map of the commonly deleted region of del (9q)	24
Figure (9):	Fundamentals of FCM and cell sorting	32
Figure (10):	Principle of FISH.....	34
Figure (11):	Cytogenetic analysis of the studied patients.....	58
Figure (12):	Immunophenotyping of the studied patients	58
Figure (13):	Relation between del (9q) and age.....	59
Figure (14):	Relation between del (9q) and hepatomegaly.....	59
Figure (15):	Relation between del (9q) and TLC	60
Figure (16):	Relation between del (9q) and platelet count.....	60
Figure (17):	Relation del (9q) and response to therapy	61
Figure (18):	Relation between del (9q) and relapse.....	61
Figure (19):	Relation between del (9q) and survival	62
Figure (20):	Relation del (9q) and prognosis	62
Figure (21):	Relation between loss of X chromosome and platelet count.....	63

List of Figures (cont...)

Fig. No.	Title	Page No.
Figure (22):	Relation between loss of X chromosome and aberrant CD19 expression.....	63
Figure (23):	Relation between presence of del (9q) or loss of X chromosome with response to therapy	64
Figure (24):	Relation between presence of del (9q) or loss of X chromosome with disease outcome.....	64
Figure (25):	Relation between response to therapy and TLC	65
Figure (26):	Relation between response to therapy and relapse.....	65
Figure (27):	Relation between response to therapy and survival	66
Figure (28):	Relation between response to therapy and disease prognosis	66
Figure (29):	Relation between disease outcome and age.....	67
Figure (30):	Relation between disease outcome and TLC	67
Figure (31):	Relation between disease outcome and BM blasts	68
Figure (32):	Relation between disease outcome and relapse.....	68
Figure (33):	Relation between disease outcome and survival	69
Figure (34):	Relation between DFS and del (9q)	69
Figure (35):	Overall survival of patients with and without del (9q).....	70
Figure (36):	Overall survival of patients with and without del (9q) or loss of X chromosome	70

List of Photos

Photo No.	Title	Page No.
Photo (1):	Vysis LSI DF RUNX1/RUNX1T1 FISH probe applied for a patient positive for t(8;21).....	71
Photo (2):	Vysis LSI ABL Spectrum Aqua FISH Probe applied for a patient with t(8;21) AML.....	71
Photo (3):	Vysis CEP X Spectrum Orange / Y Spectrum Green Probe applied for a male patient with t(8;21) AML.....	72

List of Abbreviations

Abb.	Full term
<i>AML</i>	<i>Acute myeloid leukemia</i>
<i>ANC</i>	<i>Absolute neutrophil count</i>
<i>AT</i>	<i>Adenine and thymine</i>
<i>BM</i>	<i>Bone marrow</i>
<i>BMT</i>	<i>Bone marrow transplantation</i>
<i>c DNA</i>	<i>Complementary DNA</i>
<i>CBC</i>	<i>Complete blood count</i>
<i>CBF</i>	<i>Core binding factor</i>
<i>CBFB</i>	<i>CBF subunit beta</i>
<i>CDR</i>	<i>Commonly deleted region</i>
<i>CEBPA</i>	<i>CCAAT/Enhancer-Binding Protein Alpha</i>
<i>CEP</i>	<i>Centromeric Enumeration Probe</i>
<i>CNS</i>	<i>Central nervous system</i>
<i>CR</i>	<i>Complete remission</i>
<i>CSF2RA</i>	<i>Colony-stimulating factor 2 receptor alpha</i>
<i>DAPI</i>	<i>4',6-diamidino-2-phenylindole</i>
<i>del</i>	<i>Deletion</i>
<i>der</i>	<i>Derivative</i>
<i>DFS</i>	<i>Disease free survival</i>
<i>DNA</i>	<i>Deoxyribonucleic acid</i>
<i>DW</i>	<i>Distilled water</i>
<i>EDTA</i>	<i>Ethylene Diamine Triacetic Acid</i>
<i>ETO</i>	<i>Eight twenty One</i>
<i>FAB</i>	<i>French American British</i>
<i>FBS</i>	<i>Fetal bovine serum</i>
<i>FCM</i>	<i>Flow cytometry</i>
<i>FCS</i>	<i>Fetal Calf Serum</i>
<i>FISH</i>	<i>Fluorescence in situ hybridization</i>
<i>FITC</i>	<i>Fluorescein isothiocyanate</i>

List of Abbreviations (cont...)

Abb.	Full term
<i>FLAG/ida</i>	<i>Fludara, Ara C and Granulocyte/ Idrarubocin</i>
<i>FLT</i>	<i>FMS-like tyrosine kinase</i>
<i>G banding</i>	<i>Giemsa banding</i>
<i>GC</i>	<i>Guanosine and cytosine</i>
<i>GM-CSF</i>	<i>Granulocyte-macrophage colony-stimulating factor</i>
<i>Gro</i>	<i>Groucho</i>
<i>Hb</i>	<i>Hemoglobin</i>
<i>HLA</i>	<i>Human leucocyte antigen</i>
<i>hnRNP</i>	<i>Heterogeneous nuclear ribonucleoprotein</i>
<i>HSCT</i>	<i>Hematopoietic stem cell transplantation</i>
<i>ILRA</i>	<i>Interleukin receptor alpha</i>
<i>inv</i>	<i>Inversion</i>
<i>IQR</i>	<i>Interquartile range</i>
<i>IR</i>	<i>Incomplete remission</i>
<i>KIT</i>	<i>Kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog</i>
<i>LSI ABL</i>	<i>Locus Specific Identifier Abelson</i>
<i>LSI-DF</i>	<i>Locus-Specific Identifier Dual fusion</i>
<i>MDS</i>	<i>Myelodysplastic syndrome</i>
<i>MEC</i>	<i>Mitoxontrone, Etoposide and Cyclophosphamide</i>
<i>MoAbs</i>	<i>Monoclonal antibodies</i>
<i>MPO</i>	<i>Myeloperoxidase</i>
<i>MRD</i>	<i>Minimal residual disease</i>
<i>mRNA</i>	<i>Messenger Ribonucleic Acid</i>
<i>NGS</i>	<i>Next-generation sequencing</i>
<i>OS</i>	<i>Overall survival</i>
<i>PAR</i>	<i>Pseudoautosomal region</i>

List of Abbreviations (cont...)

Abb.	Full term
<i>PB</i>	<i>Peripheral blood</i>
<i>PBS</i>	<i>Phosphate buffered saline</i>
<i>PC5</i>	<i>Phycoerythrin-cyanine 5</i>
<i>PE</i>	<i>Phycoerythrin</i>
<i>RAS</i>	<i>Rat sarcoma viral oncogene homolog</i>
<i>RNA</i>	<i>Ribonucleic acid</i>
<i>RPMI</i>	<i>Roswell Park Memorial Institute (culture medium)</i>
<i>RT-PCR</i>	<i>Reverse transcriptase polymerase chain reaction</i>
<i>RUNX</i>	<i>Runt-related transcription factor</i>
<i>RUNX1T1</i>	<i>Runt-related transcription factor1 translocation partner 1</i>
<i>SD</i>	<i>Standard deviation</i>
<i>SSC NP</i>	<i>Saline sodium citrate Nonidet P</i>
<i>t</i>	<i>Translocation</i>
<i>TLC</i>	<i>Total leucocytic count</i>
<i>TLE</i>	<i>Transducin-like enhancer of split</i>
<i>WBC</i>	<i>White blood cell</i>
<i>WHO</i>	<i>World Health Organization</i>

INTRODUCTION

Translocation (8;21) is among the most frequent recurrent chromosome aberrations in adult de novo acute myeloid leukemia (AML) (*Mrózek and Bloomfield, 2008*). It involves acute myeloid gene 1 (AML1) of chromosome 21 and eight twenty one (ETO) gene of chromosome 8 and it gives rise to AML1-ETO positive AML (*Fu et al., 2013*).

The majority of patients with t(8;21)(q22;q22) seem to have additional cytogenetic or molecular genetic abnormalities (*Klug, 2012*). These aberrations act synergetically with AML1-ETO in leukomogenesis (*Lin et al., 2008*). The two most common recurrent cytogenetic abnormalities associated with t(8;21) are loss of a sex chromosome and deletion (9q) (*Klug, 2012*). However, their impact on survival is controversial (*Lin et al., 2008*). Other abnormalities include trisomy 4 and 8, tetraploid or near-tetraploid clones (*Reikvam et al., 2011*).

The deletion of the long arm of chromosome 9 (del (9q)) is usually associated with loss of tumor suppressor genes belonging to Groucho (Gro)/ Transducin-like enhancer of split (TLE) family. Gro/TLEs have tumor suppressor-type activities in regulating cell death, apoptosis and cellular proliferation in the context of myeloid cells expressing AML1-ETO (*Dayyani et al., 2008*).

Therefore, the loss of TLE-1 and TLE-4 results in increased cell division (*Paschka and Döhner, 2013*) and significant decrease in apoptosis. Whereas, gro3 loss appears to cooperate with AML1-ETO expression to arrest myeloid differentiation and prevent migration into the bloodstream (*Dayyani et al., 2008*).

X and Y chromosomes are highly divergent in structure, except for short segments of homology called pseudoautosomal regions (PARs) that contain certain genes that may inhibit leukomogenesis by AML1-ETO (*Matsuura et al., 2012*). One gene of interest in the PARs is colony-stimulating factor 2 receptor alpha (CSF2RA), which encodes the alpha subunit of the granulocyte-macrophage colony-stimulating factor (GM-CSF) receptor (*Weng et al., 2013*).

GM-CSF reduces the self-renewal potential of AML1-ETO expressing cells and promotes myeloid differentiation (*Weng et al., 2013*). Thus, the deficiency of GM-CSF signaling may be a contributing factor to t(8;21) induced leukemia (*Matsuura et al., 2012*) by blocking of the normal differentiation and creating an enlarged pool of progenitors that are prone to malignant transformation (*Sharabi et al., 2008*).

AIM OF THE WORK

This work aims to:

Investigate the effect of additional aberrations (loss of X chromosome and del (9q)) on the clinicopathological and prognostic behavior of t(8;21) de novo AML patients.

Chapter 1

TRANSLOCATION (8;21) ACUTE MYELOID LEUKEMIA

Acute myeloid leukemia is an aggressive clonal neoplasm with maturation arrest in granulopoiesis resulting in accumulation of immature myeloblasts in the bone marrow. Genetically, it is associated with acquired genetic changes in hematopoietic progenitor cells that lead to alteration of the normal mechanisms of proliferation and differentiation (*Sultan et al., 2016*).

Studies of chromosomal abnormalities by cytogenetics followed by molecular genetics have played a prominent role in decoding the heterogeneity of AML as well as providing a profound insight into the biology of leukemia. Moreover, recurrent chromosomal and molecular abnormalities that are detected at diagnosis have provided valuable prognostic information such as response to induction chemotherapy, relapse risk and overall survival (OS) (*Ilyas et al., 2015*).

Conventional karyotyping is the cornerstone of risk stratification in AML, classifying AML into favorable, unfavorable and intermediate-risk prognostic groups. The cytogenetic favorable group includes patients with t(15;17)(q22;q12) and the core binding factor AML (*He et al., 2015*).